Effect of L-Acetylcarnitine on body composition in HIV-related lipodystrophy

Hormone and Metabolic Research

Volumn 41, Issue 11, 2009, Pages 840-845

  Benedini, S ^b,c   Perseghin, G ^b,c   Terruzzi, I ^b   Scifo, P ^b   Invernizzi, P L ^c   Del Maschio, A ^b   Lazzarin, A ^b   Luzi, L ^a,b,c  

^a Clinical Research Unit II   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Energy metabolism; Human immunodeficiency virus; Insulin sensitivity; Nmr spectroscopy

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; INTRAMYOCELLULAR TRIGLYCERIDE; LEVACECARNINE; LIPID; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; INSULIN SENSITIVITY; LIPID OXIDATION; LIPID STORAGE; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RESPIRATORY QUOTIENT; SOLEUS MUSCLE;

ACETYLCARNITINE; ADULT; BLOOD GLUCOSE; BODY COMPOSITION; CASE-CONTROL STUDIES; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN; LIPIDS; MIDDLE AGED;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70649107950     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1225625     Document Type: Article

References (36)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58 (Pubitemid 28190689)
2. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, Gastaut JA, Touraine JL. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-1667
3. Capiluppi B, Ciuffreda D, Sciandra M, Marroni M, Tambussi C, Lazzarin A. Metabolic disorders in a cohort of patients treated with highly aggressive antiretroviral therapies during primary HIV-1 infection. AIDS 2000; 14: 1861-1862
4. Luzi L, Perseghin G, Tambussi G, Meneghini E, Scifo P, Pagliatl E, Maschio A, Testolin G, Lazzarin A. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 2003; 284: E274-E280
5. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003; 63: 2555-2574 (Pubitemid 37491560)
6. Renard E, Fabre J, Paris F, Reynes J, Bringer J. Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol (Oxf) 1999; 51: 223-230 (Pubitemid 29378908)
7. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Grinspoon S, Gertner J. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86: 504-510
8. Jorgensen JO, Krag M, Kanaley J, Moller J, Hansen TK, Moller N, Christiansen JS, Orskov H. Exercise, hormones, and body temperature regulation and action of GH during exercise. J Endocrinol Invest 2003; 26: 838-842 (Pubitemid 38049165)
9. Murray RD, Adams JE, Shalet SM. Adults with partial growth hormone deficiency have an adverse body composition. J Clin Endocrinol Metab 2004; 89: 1586-1591
10. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1998; 21 (Suppl 1): S5-S19
11. Polo M, Galli M, Scientmark T, Walli R. Proposal for a clinical and metabolic classification of metabolic and hormone abnormalities under HAART. In: Int Workshop 2nd on HIV-related Lipodystrophy. Marrakesh, Morocco; 2000
12. Luzi L, Castellino P, DeFronzo RA. Insulin and hyperaminoacidemia regulate by a different mechanism leucine turnover and oxidation in obesity. Am J Physiol Endocrinol Metab 1996; 270: E273-E281 (Pubitemid 126756197)
13. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, Luzi L. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999; 48: 1600-1606
14. Perseghin G, Scifo P, Danna M, Battezzati A, Benedini S, Meneghini E, Del Maschio A, Luzi L Normal insulin sensitivity and IMCL content in overweight humans are associated with higher fasting lipid oxidation. Am J Physiol Endocrinol Metab 2002; 283: E556-E564
15. Matthews DR, HoskerJP, Rudenskl AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
16. Perseghin G, Caumo A, Piceni Sereni L, Battezzati A, Luzi L. Fasting blood sample-based assessment of insulin sensitivity in kidney- pancreastransplanted patients. Diabetes Care 2002; 25: 2207-2211
17. Perseghin G, Caumo A, Caloni M, Testolin G, Luzi L. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals. J Clin Endocrinol Metab 2001; 86: 4776-4781
18. van der Valk M, Allick G, Weverling GJ, Romijn JA, Ackermans MT, Lange JM, van Eck-Smit BL, van Kuijk C, Endert E, Sauerwein HP, Reiss P. Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients. J Clin Endocrinol Metab 2004; 89: 3554-3560 (Pubitemid 38951934)
19. Haugaard SB, Andersen O, Dela F, Holst JJ, Storgaard H, Fenger M, Iversen J, Madsbad S. Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells. Eur J Endocrinol 2005; 152: 103-112 (Pubitemid 40185458)
20. Wutzke KD, Lorenz H. The effect of L-carnitine on fat oxidation, protein turnover, and body composition in slightly overweight subjects. Metabolism 2004; 53: 1002-1006 (Pubitemid 38988283)
21. Mingrone G, Greco AV, Capristo E, Benedetti G, Giancaterini A, De Gaetano A, Gasbarrini G. 1-Carnitine improves glucose disposal in type 2 diabetic patients. J Am Coll Nutr 1999; 18: 77-82
22. Reynier M, Brun JF, Orsetti A. Metabolic effects of L-carnitine, L-lysine methionine during maximal exercise. Sci Sport 1996; 13: 17-25
23. De Gaetano A, Mingrone G, Castagneto M, Calvani M. Carnitine increases glucose disposal in humans. J Am Coll Nutr 1999; 18: 289-295
24. Luzi L, Meneghini E, Oggionni S, Tambussi G, Piceni-Sereni L, Lazzarin A. GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study. Eur J Endocrinol 2005; 153: 781-789 (Pubitemid 43020228)
25. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology 1999; 140: 3188-3196
26. Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM. Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002; 87: 5630-15563 (Pubitemid 36034370)
27. He Q, Engelson ES, Albu JB, Heymsfield SB, Kotler DP. Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy. J Appl Physiol 2003; 94: 2051-2057
28. Kotier DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, Saag M, Bock D, Simons G, GertnerJM. Serostim in Adipose Redistribution Syndrome Study Group. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35: 239-252
29. Sutinen J, Kannisto K, Korsheninnikova E, Nyman T, Ehrenborg E, Andrew R, Wake DJ, Hamsten A, Walker BR, Yki-Järvinen H. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of Cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004; 47: 1668-1671
30. Buyse J, Janssens GP, Decuypere E. The effects of dietary L-carnitine supplementation on the performance, organ weights and circulating hormone and metabolite concentrations of broiler chickens reared under a normal or low temperature schedule. Br Poult Sci 2001; 42: 230-241 (Pubitemid 33731098)
31. Kraemer WJ, Volek JS, French DN, Rubin MR, Sharman MJ, Gomes AL, Ratamess NA, Newton RU, Jemiolo B, Craig BW, Häkkinen K. The effects of amino acid supplementation on muscular performance during resistance training overreaching. J Strength Cond Res 2003; 17: 250-258 (Pubitemid 36745488)
32. Parr TB. A new technique to elevate night time growth hormone release and a potential growth hormone feedback control loop. Med Hypotheses 2001; 56: 610-613
33. Di Marzio L, Moretti S, D'Alòa S, Zazzeronia F, Marcellini S, Smacchia C, Alesse E, Cifone MC, De Simone C. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Clin Immunol 1999; 92: 103-110
34. Benedini S, Tenuzzi I, Lazzarin A, Luzi L. Recombinant Human Growth hormone for the Treatment of HIV-Associated Adipose Redistribution Syndrome. BioDrugs 2008; 22: 101-112
35. Falutz J, Alias S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessei J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007; 357: 2359-2370
36. Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, Hemphill L, Lee H, Grinspoon S. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008; 300: 509-519